Content about Thrombosis

April 24, 2013
Dollar General to donate $2,000 to blood-clot education effort

Dollar General will benefit a nonprofit outreach program focused on blood clots, the discount store chain said.

GOODLETTSVILLE, Tenn. — Dollar General will benefit a nonprofit outreach program focused on blood clots, the discount store chain said.

Dollar General announced it would match the $2,000 donation that NASCAR Nationwide Series driver Brian Vickers made to Clot Connect. Vickers was diagnosed in early 2010 with blood clots that forced him to miss the remainder of the season and worked with University of North Carolina at Chapel Hill physicians and Clot Connect to make informed decisions on his healthcare.

November 8, 2012
Study: Aspirin effective in preventing clots following joint replacement surgery

Recent research from the Rothman Institute at Jefferson has shown aspirin to be just as effective in preventing clots — specifically pulmonary emboli, life-threatening blood clots that can develop in the arteries of the lungs following joint replacement surgery — Thomas Jefferson University announced Wednesday.

PHILADELPHIA – Recent research from the Rothman Institute at Jefferson has shown aspirin to be just as effective in preventing clots — specifically pulmonary emboli, life-threatening blood clots that can develop in the arteries of the lungs following joint replacement surgery — Thomas Jefferson University announced Wednesday. 

November 5, 2012
FDA approves J&J anti-clotting drug

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating internal blood clots, the company said.

RARITAN, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating internal blood clots, the company said.

J&J subsidiary Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) for treating deep-vein thrombosis and pulmonary embolism and to reduce the risk of recurrence of the clotting conditions after initial treatment.

The company said Xarelto was the first oral anticoagulant approved to treat DVT and PE without the need for injections or routine blood-monitoring.

July 9, 2012
FDA gives priority review to J&J drug

The Food and Drug Administration has given priority review to a drug as a treatment for blood-clot disorders, the manufacturer said Monday.

RARITAN, N.J. — The Food and Drug Administration has given priority review to a drug as a treatment for blood-clot disorders, the manufacturer said Monday.

Johnson & Johnson subsidiary Janssen Research & Development said the FDA had given the priority review status to its applications for Xarelto (rivaroxaban) as a treatment for deep-vein thrombosis — a condition in which clots form in one of the large deep veins, usually in the legs — and pulmonary embolism, which occurs when a DVT clot dislodges and is carried to the lung via the heart.

May 3, 2012
J&J seeks additional approval for anti-clotting drug

Drug maker Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat patients with deep vein thrombosis or pulmonary embolism, the company said.

RARITAN, N.J. — Drug maker Johnson & Johnson is seeking approval from the Food and Drug Administration for a drug to treat patients with deep vein thrombosis or pulmonary embolism, the company said.

J&J division Janssen Research & Development announced the submission of a supplemental new drug application for Xarelto (rivaroxaban) to the FDA for the two conditions and for preventing recurrent venous thromboembolism.

November 7, 2011
FDA approves J&J's Xarelto for stroke prevention

The Food and Drug Administration has approved a drug made by Johnson & Johnson for preventing stroke in patients with abnormal heart rhythm, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for preventing stroke in patients with abnormal heart rhythm, the agency said.

The agency announced Friday the approval of Xarelto (rivaroxaban), an anti-clotting made by J&J subsidiary Janssen Pharmaceuticals, in patients with non-valvular atrial fibrillation. The FDA approved the drug in the 10-mg strength in July for deep-vein thrombosis in patients receiving knee and hip replacement surgery. The latest approval includes 15-mg and 20-mg strengths.

July 5, 2011
Xarelto OKed by FDA

The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said Friday.

RARITAN, N.J. — The Food and Drug Administration has approved a drug made by Johnson & Johnson for treating deep vein thrombosis in patients undergoing knee or hip replacement surgery, a J&J subsidiary said Friday.

Janssen Pharmaceuticals announced the approval of Xarelto (rivaroxaban) tablets as a once-daily oral anticoagulant for DVT, a condition that could lead to pulmonary embolism.

March 7, 2010
Clinical study: Pfizer-Bristol anticoagulant more effective than competitior

A pill-based anticoagulant drug under development by Pfizer and Bristol-Myers Squibb worked better in reducing...